News stories about Tenax Therapeutics (NASDAQ:TENX) have been trending somewhat positive on Saturday, according to Accern Sentiment Analysis. The research firm ranks the sentiment of news coverage by analyzing more than 20 million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Tenax Therapeutics earned a news sentiment score of 0.11 on Accern’s scale. Accern also assigned news articles about the specialty pharmaceutical company an impact score of 45.3056359104933 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the near future.

Tenax Therapeutics (NASDAQ:TENX) traded down 0.477% during midday trading on Friday, reaching $0.417. 477,590 shares of the company traded hands. Tenax Therapeutics has a 12-month low of $0.31 and a 12-month high of $2.65. The stock’s market capitalization is $11.77 million. The company has a 50 day moving average of $0.37 and a 200-day moving average of $0.49.

TRADEMARK VIOLATION NOTICE: This piece was reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this piece on another site, it was illegally copied and republished in violation of United States & international trademark and copyright legislation. The original version of this piece can be viewed at

Tenax Therapeutics Company Profile

Tenax Therapeutics, Inc is a specialty pharmaceutical company. The Company is focused on identifying, developing and commercializing products for the critical care market. The Company’s main product is levosimendan. Levosimendan is a calcium sensitizer developed for intravenous use in hospitalized patients with acutely decompensated heart failure.

Insider Buying and Selling by Quarter for Tenax Therapeutics (NASDAQ:TENX)

Receive News & Stock Ratings for Tenax Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tenax Therapeutics Inc. and related stocks with our FREE daily email newsletter.